Last reviewed · How we verify
TQ-B3101
At a glance
| Generic name | TQ-B3101 |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects (PHASE1)
- A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor (PHASE2)
- A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) (PHASE2)
- Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQ-B3101 CI brief — competitive landscape report
- TQ-B3101 updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI